Cyclacel Pharmaceuticals, Inc. (CYCCP)

Cyclacel Pharmaceuticals, Inc. (CYCCP) Healthcare & Pipeline Overview

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biotechnology firm specializing in cancer and proliferative disorder therapies, advancing a pipeline of investigational cyclin-dependent kinase and polo-like kinase inhibitors, alongside a novel nucleoside analog, through Phase 1/2 and Phase 2 clinical evaluations for various oncological indications.

What Is the Investment Thesis for CYCCP?

Cyclacel Pharmaceuticals, Inc. presents a research-stage profile centered on its clinical pipeline targeting various cancers and proliferative disorders. The company's value proposition is intrinsically linked to the successful progression and eventual commercialization of its investigational therapies, including Fadraciclib, CYC140, and Sapacitabine, all in Phase 1/2 or Phase 2 trials. Key growth catalysts involve positive data readouts from these ongoing clinical studies, which could de-risk the assets and attract potential partnership or licensing opportunities. The collaboration with MD Anderson Cancer Center further validates its research efforts and provides a robust clinical development platform. Financially, the company operates with a market capitalization of $11.31M and a significant negative profit margin of -204.2%, typical for a clinical-stage biopharmaceutical firm reliant on R&D investment rather than product sales. Its gross margin stands at 18.4%, reflecting early-stage operations. The low beta of 0.16 suggests relatively low volatility compared to the broader market, though this can be misleading for micro-cap biotech firms. The primary risks include the high failure rate inherent in drug development, regulatory hurdles, intense competition in oncology, and the continuous need for capital to fund clinical trials.

Based on FMP financials and quantitative analysis

CYCCP Key Highlights

• Market Capitalization: Cyclacel Pharmaceuticals, Inc. maintains a market capitalization of $11.31M, reflecting its status as a micro-cap clinical-stage biopharmaceutical company.
• Profitability: The company reported a profit margin of -204.2%, indicative of a research and development-intensive business model prior to commercialization and product revenue generation.
• Gross Margin: Cyclacel's gross margin stands at 18.4%, which is observed in the context of its early-stage operations and limited revenue from product sales.
• Market Volatility (Beta): With a beta of 0.16, the stock has historically exhibited lower volatility relative to the overall market, though this metric can be less predictive for small-cap biotech firms.
• Employee Base: The company operates with a lean team of 12 employees, focusing resources primarily on its core research and clinical development activities.

Who Are CYCCP's Competitors?

CYCCP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CYCCP's Key Strengths?

• Diverse pipeline of investigational therapies targeting multiple cancer types and proliferative disorders.
• Clinical-stage assets (Fadraciclib, CYC140, Sapacitabine) in Phase 1/2 or Phase 2 trials.
• Strategic clinical collaboration with the University of Texas MD Anderson Cancer Center.
• Focus on well-validated targets like CDKs, PLKs, and nucleoside analogs.

What Are CYCCP's Weaknesses?

• Significant negative profit margin (-204.2%) indicative of pre-revenue stage.
• Small market capitalization ($0.01B) and limited employee base (12 employees).
• High capital requirements for ongoing and future clinical trials.
• Reliance on successful clinical trial outcomes for future viability.

What Could Drive CYCCP Stock Higher?

• Fadraciclib Phase 1/2 Data Readouts: Anticipated release of further clinical data from the ongoing Phase 1/2 trials for Fadraciclib, both as a monotherapy for solid tumors and in combination with venetoclax for relapsed or refractory chronic lymphocytic leukemia. Positive results could validate its therapeutic potential and influence future development decisions.
• CYC140 Phase 1/2 Clinical Progress: Continued advancement and enrollment in the Phase 1/2 trials for CYC140, a polo-like kinase inhibitor, for advanced leukemias and various solid tumor types. Key milestones include patient enrollment updates and initial safety/efficacy signals.
• Sapacitabine Phase 1/2 Development: Ongoing clinical investigation of Sapacitabine in Phase 1/2 trials for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Updates on trial progress and preliminary data could provide insights into its potential in these hematological malignancies.
• Investigator-Sponsored Trial Updates for Seliciclib: Potential updates or data presentations from investigator-sponsored trials (ISTs) of Seliciclib in Phase 2 for Cushing's disease and Phase 1/2 for advanced rheumatoid arthritis, which could expand the drug's potential applications.
• MD Anderson Collaboration Milestones: Continued progress and potential data generation from the clinical collaboration with the University of Texas MD Anderson Cancer Center, assessing three of Cyclacel's compounds in various hematological malignancies.

What Are the Key Risks for CYCCP?

• Negative return on equity (-51.2%) — the business is not currently generating profit on shareholder capital.
• Insider selling — insiders were net sellers of roughly $7.5M recently.
• High Clinical Development Risk: The inherent risk of failure in clinical trials is substantial, with many drug candidates failing to demonstrate sufficient efficacy or safety to gain regulatory approval. This could lead to significant financial losses and delays.
• Regulatory Hurdles: The company faces stringent regulatory requirements from health authorities (e.g., FDA, EMA) for drug approval. Any delays, additional data requests, or outright rejections could significantly impact commercialization timelines and costs.
• Funding and Capital Requirements: As a clinical-stage company with a negative profit margin, Cyclacel Pharmaceuticals, Inc. relies heavily on external funding. There is an ongoing risk of needing to raise additional capital, potentially through dilutive equity offerings, to finance its extensive R&D activities and clinical trials.
• Intense Market Competition: The biotechnology and oncology markets are highly competitive, with numerous companies developing similar or alternative therapies. Cyclacel's drug candidates may face challenges in demonstrating superior efficacy or safety compared to existing or emerging treatments.
• Intellectual Property Challenges: The company's success depends on its ability to obtain, maintain, and enforce patent protection for its drug candidates. Challenges to its intellectual property rights could undermine its competitive position and future revenue potential.

What Are the Growth Opportunities for CYCCP?

• Fadraciclib Development for Solid Tumors and CLL: Fadraciclib, a cyclin-dependent kinase (CDK) inhibitor, is currently in Phase 1/2 clinical evaluation. Its development as a monotherapy for solid tumors and in combination with venetoclax for relapsed or refractory chronic lymphocytic leukemia (CLL) represents a significant growth opportunity. The global market for solid tumor therapies is substantial, projected to reach hundreds of billions of dollars, while the CLL market also represents a multi-billion dollar segment. Successful progression through these trials, demonstrating favorable safety and efficacy profiles, could lead to accelerated development pathways and attract significant pharmaceutical partnerships, potentially within the next 3-5 years.
• CYC140 for Advanced Leukemias and Solid Tumors: CYC140, a polo-like kinase (PLK) inhibitor, is also progressing through Phase 1/2 trials for advanced leukemias and various solid tumor types. PLK inhibitors target a crucial pathway in cell division, making them attractive candidates for a broad spectrum of cancers. The leukemia market alone is a multi-billion dollar opportunity, with solid tumors offering an even larger addressable market. Positive clinical data from these trials, expected over the next 2-4 years, could validate CYC140's potential as a novel therapeutic agent, opening doors for further clinical development and commercialization discussions.
• Sapacitabine for AML and MDS: Sapacitabine, an orally available prodrug of CNDAC and a novel nucleoside analog, is in Phase 1/2 clinical investigation for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Both AML and MDS are severe hematological malignancies with significant unmet needs for effective and tolerable treatments. The global AML and MDS markets are collectively valued in the billions of dollars and are expected to grow. Demonstrating clinical benefit and an improved safety profile for Sapacitabine could position it as a valuable treatment option, with key data milestones anticipated within the next 2-3 years.
• Seliciclib in Investigator-Sponsored Trials: Seliciclib, another CDK inhibitor, is being explored in investigator-sponsored trials (ISTs) for Cushing's disease (Phase 2) and advanced rheumatoid arthritis (Phase 1/2). While ISTs are not directly company-funded, positive results can generate valuable data, expand the potential indications for the compound, and attract external funding or partnerships for further development. Cushing's disease and rheumatoid arthritis represent distinct, multi-billion dollar markets. Success in these trials, potentially yielding data within the next 3-5 years, could broaden Cyclacel's therapeutic scope beyond oncology and create new revenue streams through licensing.
• Strategic Clinical Collaboration with MD Anderson Cancer Center: The ongoing clinical collaboration with the University of Texas MD Anderson Cancer Center is a significant growth driver. This partnership assesses the safety and effectiveness of three of Cyclacel's compounds in various hematological malignancies. Collaborations with leading cancer centers provide access to expert clinicians, patient populations, and robust research infrastructure, accelerating clinical development and enhancing data quality. Successful outcomes from this collaboration, expected over the next 1-3 years, could significantly de-risk the pipeline, validate the scientific approach, and enhance the company's credibility for future funding rounds or strategic alliances.

What Opportunities Does CYCCP Have?

• Positive data readouts from ongoing Phase 1/2 and Phase 2 clinical trials.
• Potential for strategic partnerships, licensing agreements, or acquisitions by larger pharmaceutical companies.
• Expansion of indications for existing pipeline assets, such as Seliciclib in non-oncology areas.
• Addressing significant unmet medical needs in various cancer types and rare diseases.

What Threats Does CYCCP Face?

• High failure rates inherent in clinical drug development and regulatory approval processes.
• Intense competition from other biotechnology and pharmaceutical companies developing similar therapies.
• Need for continuous funding, with potential for dilution through equity raises.
• Adverse clinical trial results or safety concerns halting development.

What Are CYCCP's Competitive Advantages?

• Proprietary Drug Candidates: Development of novel, small-molecule drug candidates like Fadraciclib, CYC140, and Sapacitabine, which target specific biological pathways.
• Intellectual Property: Potential for patent protection on its investigational compounds and their methods of use, providing exclusivity for a period.
• Clinical Trial Progress: Advancement of multiple compounds through Phase 1/2 and Phase 2 clinical trials, building a body of evidence for safety and efficacy.
• Strategic Collaborations: Partnership with a renowned institution like the MD Anderson Cancer Center, lending credibility and expertise to its clinical development programs.
• Targeted Mechanisms: Focus on specific, well-understood cellular mechanisms (CDK, PLK, nucleoside analogs) with potential for high therapeutic impact in oncology.

What Does CYCCP Do?

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing therapeutic solutions for cancer and various other proliferative disorders. Headquartered in Berkeley Heights, New Jersey, the company operates with a focused team of 12 employees, emphasizing research and development in oncology. At the forefront of its pipeline are several investigational therapies. Fadraciclib, a cyclin-dependent kinase (CDK) inhibitor, is currently undergoing Phase 1/2 clinical evaluation. It is being assessed as a monotherapy for solid tumors and in combination with venetoclax for managing relapsed or refractory chronic lymphocytic leukemia. Another promising candidate is CYC140, a polo-like kinase inhibitor, also progressing through Phase 1/2 trials for advanced leukemias and various solid tumor types. The pipeline further features Sapacitabine, an orally available prodrug of CNDAC and a novel nucleoside analog. This compound is in Phase 1/2 clinical investigation for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Additionally, seliciclib, another CDK inhibitor, is being explored in investigator-sponsored trials (ISTs), specifically in Phase 2 for Cushing's disease and Phase 1/2 for advanced rheumatoid arthritis. Underscoring its commitment to research, Cyclacel maintains a clinical collaboration with the University of Texas MD Anderson Cancer Center. This partnership aims to assess the safety and effectiveness of three of its compounds in patients suffering from various hematological malignancies, including chronic lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndromes, and other advanced forms of leukemia. The company's strategic focus is on developing small molecule drugs that target cell cycle, transcriptional regulation, and DNA damage response pathways, aiming to address significant unmet medical needs in oncology and beyond.

What Products and Services Does CYCCP Offer?

• Develops clinical-stage biopharmaceutical therapies for cancer and proliferative disorders.
• Focuses on small molecule drugs targeting cell cycle, transcriptional regulation, and DNA damage response pathways.
• Advances Fadraciclib, a CDK inhibitor, through Phase 1/2 trials for solid tumors and chronic lymphocytic leukemia.
• Progresses CYC140, a PLK inhibitor, through Phase 1/2 trials for advanced leukemias and solid tumors.
• Investigates Sapacitabine, a novel nucleoside analog, in Phase 1/2 for acute myeloid leukemia and myelodysplastic syndrome.
• Supports investigator-sponsored trials for Seliciclib in Cushing's disease and rheumatoid arthritis.
• Maintains a clinical collaboration with the University of Texas MD Anderson Cancer Center for pipeline compounds.
• Conducts research and development to address unmet medical needs in oncology and other proliferative diseases.

How Does CYCCP Make Money?

• Research and Development Focus: Operates primarily as a clinical-stage biopharmaceutical company, investing heavily in the discovery and development of novel drug candidates.
• Pipeline Advancement: Generates value by progressing its investigational therapies through various phases of clinical trials, aiming to demonstrate safety and efficacy.
• Potential Licensing/Partnerships: Seeks to monetize its drug candidates through future licensing agreements, collaborations, or outright sales to larger pharmaceutical companies upon successful clinical development.
• Equity Financing: Relies on equity financing, grants, and strategic alliances to fund its extensive research and development activities, given its pre-commercialization stage.
• Future Product Sales: Aims for eventual revenue generation from the commercial sale of approved drugs, following successful regulatory approval and market launch.

What Industry Does CYCCP Operate In?

Cyclacel Pharmaceuticals, Inc. operates within the highly specialized and competitive biotechnology industry, specifically focusing on oncology and proliferative disorders. The global oncology drug market is characterized by significant unmet medical needs, continuous innovation, and substantial investment in research and development. Key trends include the rise of targeted therapies, immunotherapies, and precision medicine, alongside an increasing understanding of cell cycle regulation and DNA damage response pathways. Cyclacel's pipeline, featuring CDK and PLK inhibitors and a nucleoside analog, positions it within the targeted therapy segment, aiming to disrupt specific cellular mechanisms implicated in cancer. The competitive landscape is intense, populated by both large pharmaceutical companies with extensive resources and numerous smaller biotech firms vying for breakthroughs. Cyclacel's strategy involves advancing novel drug candidates through early-to-mid-stage clinical trials, seeking to demonstrate efficacy and safety that could differentiate its compounds in a crowded market. Success in this industry is heavily dependent on clinical trial outcomes, regulatory approvals, and the ability to secure funding or strategic partnerships.

Who Are CYCCP's Key Customers?

• Patients: Ultimately, patients suffering from cancer (solid tumors, leukemias, CLL, AML, MDS) and other proliferative disorders (Cushing's disease, rheumatoid arthritis) are the end beneficiaries of its therapeutic developments.
• Healthcare Providers: Oncologists, hematologists, endocrinologists, and rheumatologists who would prescribe and administer the company's approved drugs.
• Research Institutions: Collaborating institutions like the University of Texas MD Anderson Cancer Center, which participate in clinical trials and contribute to scientific understanding.
• Pharmaceutical Partners: Potential future partners who might license or acquire the company's drug candidates for further development and commercialization.

Net buyingInsider Activity

The most recent 12 insider filings for Cyclacel Pharmaceuticals, Inc. break down as 7 sales and 5 purchases. On net that is roughly 939K shares acquired (about $7.5M) — insiders putting money in tends to read as conviction.

FY2026 estForward Outlook

Wall Street analysts project Cyclacel Pharmaceuticals, Inc. revenue of about $100K for fiscal 2026, with EPS near $-268.80.

3/3 beatsEarnings Track Record

Cyclacel Pharmaceuticals, Inc. has beaten Wall Street's EPS estimate in 3 of its last 3 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 97.1% above estimates on average.

F-Score 4/9Financial Health

Cyclacel Pharmaceuticals, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.

ROE -51%Key Financial Metrics

Return on equity for Cyclacel Pharmaceuticals, Inc. stands at -51.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -41.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -90.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.06 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -62.7%, the inverse of the P/E and a quick read on earnings relative to price.

Cyclacel Pharmaceuticals, Inc. (CYCCP) Valuation Context

Valued at $11.31M, CYCCP is classified as a micro-cap stock. Relative to its peer group, CYCCP's quantitative score of 61/100 is below the peer average of 76/100.

CYCCP Revenue & Earnings Trend

In Q1 2026, CYCCP generated $778K in top-line revenue, marking a sequential increase of 16.8%. The company recorded a net loss of $197K, with diluted EPS of $-0.04. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, CYCCP averaged $-0.38 in diluted EPS.

Company Profile

Cyclacel Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Berkeley Heights, US. The company is led by CEO Sing Ee Wong. CYCCP has traded publicly since 2005.

CYCCP Financials

CYCCP Latest News

No recent news available for CYCCP.

CYCCP Analyst Consensus

CYCCP MoonshotScore

CYCCP Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources